# Immunology * **Definition:** The branch of biomedical science that deals with the study of the immune system, including its structure, function, disorders, and diseases. * **Taxonomy:** Specialties / Immunology ## News * Selected news on the topic of **Immunology**, for healthcare technology leaders * 8.6K news items are in the system for this topic * Posts have been filtered for tech-related keywords | Date | Title | Source | | --- | --- | --- | | 5/20/2025 | [**Three Physicians at Allergy & Asthma Associates of Michigan Named 2025 Castle Connolly ...**](https://www.prnewswire.com/news-releases/three-physicians-at-allergy--asthma-associates-of-michigan-named-2025-castle-connolly-top-doctors-for-the-10th-consecutive-year-302458459.html) | [[PR Newswire]] | | 4/15/2025 | [**Illumina and Tempus look beyond cancer in new AI-driven genomics deal**](https://firstwordpharma.com/story/5950055) | [[FirstWord PHARMA]] | | 4/10/2025 | [**Evaxion to present at World Vaccine Congress - Yahoo Finance**](https://finance.yahoo.com/news/evaxion-present-world-vaccine-congress-120000933.html) | [[Yahoo Finance]] | | 4/5/2025 | [**Safety and Efficacy Updates for Asthma and Urticaria Therapies**](https://www.ajmc.com/view/safety-and-efficacy-updates-for-asthma-and-urticaria-therapies) | [[AJMC]] | | 4/3/2025 | [**35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ...**](https://www.prnewswire.com/news-releases/35-year-industry-academic-partnership-yielding-groundbreaking-advances-for-science-and-patients-renews-for-another-three-years-between-la-jolla-institute-for-immunology-and-kyowa-kirin-302420448.html) | [[PR Newswire]] | | 3/28/2025 | [**Supercomputer uncovers immune system's secret to self-tolerance**](https://medicalxpress.com/news/2025-03-supercomputer-uncovers-immune-secret-tolerance.html) | [[MedicalXpress]] | | 3/18/2025 | [**Seismic Therapeutic Forms Translational Medicine Advisory Board with Prominent Experts ...**](https://finance.yahoo.com/news/seismic-therapeutic-forms-translational-medicine-120000345.html) | [[Yahoo Finance]] | | 3/1/2025 | [**Is Twist Bioscience Corporation (TWST) The Best Immunology Stock To Buy Now? - Yahoo Finance**](https://finance.yahoo.com/news/twist-bioscience-corporation-twst-best-193849713.html) | [[Yahoo Finance]] | | 3/1/2025 | [**Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?**](https://finance.yahoo.com/news/beigene-ltd-onc-best-immunology-194228024.html) | [[Yahoo Finance]] | | 3/1/2025 | [**Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?**](https://finance.yahoo.com/news/exelixis-inc-exel-best-immunology-193804546.html) | [[Yahoo Finance]] | | 1/28/2025 | [**AI advancement in T cell epitope prediction could propel vaccine development**](https://medicalxpress.com/news/2025-01-ai-advancement-cell-epitope-propel.html) | [[MedicalXpress]] | | 12/19/2024 | [**Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases**](http://www.businesswire.com/news/home/20241219653670/en/Palleon-Pharmaceuticals-and-Henlius-Collaborate-to-Advance-Glycan-Editing-as-a-Treatment-for-Autoimmune-Diseases/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/16/2024 | [**FairJourney Biologics Establishes Scientific Advisory Board**](http://www.businesswire.com/news/home/20241216463838/en/FairJourney-Biologics-Establishes-Scientific-Advisory-Board/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/2/2024 | [**JAMA**](https://jamanetwork.com/journals/jama/fullarticle/2827395) | [[JAMA Network]] | | 11/13/2024 | [**GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into Immunology**](http://www.businesswire.com/news/home/20241112337557/en/GenEdit-Appoints-Dr.-J.-Rodrigo-Mora-as-Chief-Scientific-Officer-to-Expand-Its-NanoGalaxy%C2%AE-Genetic-Medicine-Platform-into-Immunology/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 11/13/2024 | [**GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy ...**](https://www.businesswire.com/news/siliconvalley/20241112337557/en) | [[Business Wire]] | | 10/21/2024 | [**Immunology Collaboration and Licensing Agreements Trends Report 2024 with Directory of ...**](https://www.businesswire.com/news/home/20241021148151/en/Immunology-Collaboration-and-Licensing-Agreements-Trends-Report-2024-with-Directory-of-862-Deals-Singed-Since-2016---Upfront-Milestone-Royalties-by-Company-A-Z-Therapy-Focus-and-Technology---ResearchAndMarkets.com) | [[Business Wire]] | | 10/21/2024 | [**Immunology Collaboration and Licensing Agreements Trends Report 2024 with Directory of 862 Deals Singed Since 2016 - Upfront, Milestone, Royalties by Company A-Z, Therapy Focus and Technology - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241021148151/en/Immunology-Collaboration-and-Licensing-Agreements-Trends-Report-2024-with-Directory-of-862-Deals-Singed-Since-2016---Upfront-Milestone-Royalties-by-Company-A-Z-Therapy-Focus-and-Technology---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 10/14/2024 | [**Immunology Collaboration and Licensing Agreements Trends Report 2024 - Yahoo Finance**](https://finance.yahoo.com/news/immunology-collaboration-licensing-agreements-trends-104600251.html) | [[Yahoo Finance]] | | 10/9/2024 | [**Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials**](https://www.globenewswire.com/news-release/2024/10/09/2960432/0/en/Strong-validation-of-Evaxion-s-AI-Immunology-platform-in-multiple-clinical-trials.html) | [[Globe Newswire]] | | 10/9/2024 | [**Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials**](https://finance.yahoo.com/news/strong-validation-evaxion-ai-immunology-120000497.html) | [[Yahoo Finance]] | | 10/2/2024 | [**Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform**](https://markets.businessinsider.com/news/stocks/recent-clinical-data-confirms-significantly-improved-predictive-power-of-evaxion-s-ai-immunology-platform-1033817918) | [[Business Insider Markets]] | | 8/28/2024 | [**Immunology Market to Reach $204.0 Billion, Globally, by 2033 at 6.3AGR: Allied Market Research**](https://www.globenewswire.com/news-release/2024/08/28/2936850/0/en/Immunology-Market-to-Reach-204-0-Billion-Globally-by-2033-at-6-3-CAGR-Allied-Market-Research.html) | [[Globe Newswire]] | | 8/27/2024 | [**Synthetic immunology: Approaching a turning point in the treatment and prevention of disease**](https://medicalxpress.com/news/2024-08-synthetic-immunology-approaching-treatment-disease.html) | [[MedicalXpress]] | | 8/15/2024 | [**Genentech to shut down cancer immunology research department amid broader R&D rethink**](https://www.fiercebiotech.com/biotech/genentech-shut-down-cancer-immunology-department-amid-broader-downsizing-efforts) | [[FierceBiotech]] | ## Specialty Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **NImmune Biopharma**: A company focused on developing immunoregulatory drugs, collaborating with BioTherapeutics to enhance its drug pipeline. - **Northwestern Medicine**: A research institution that has made significant discoveries in immunology, particularly regarding regulatory T-cells and their role in autoimmune diseases and cancer. - **UCLA**: A leading research institution that has established the California Institute for Immunology and Immunotherapy, focusing on rapid vaccine development and microbiome research. - **Human Immunology Biosciences (HI-Bio)**: A company specializing in targeted treatments for autoimmune diseases, known for its lead program, felzartamab, a monoclonal antibody in clinical development. - **Infinity Bio**: A startup utilizing proprietary technology for antibody profiling, aiming to enhance therapeutic and diagnostic development in immunology. - **Biogen**: A biotechnology company focused on developing therapies for neurological and immunological diseases, recently acquired Human Immunology Biosciences to enhance its immunology portfolio. - **AbbVie**: A biopharmaceutical company known for its immunology products and the Immunology Scholarship program supporting students with chronic immune-mediated diseases. - **Johnson & Johnson**: A major player in the immunology sector, known for its successful treatments like Tremfya for psoriasis. - **Tolerance Bio**: A company developing therapies to manipulate the thymus for immune diseases, supported by a strong advisory board. - **Kymera Therapeutics**: A biotech firm shifting focus from oncology to immunology, developing therapies for various inflammatory conditions. - **Odyssey Therapeutics**: A biotech firm specializing in immunology, collaborating with Terray Therapeutics to develop small molecule medicines targeting autoimmune diseases. - **BeiGene, Ltd.**: A biotechnology company focusing on oncology treatments and developing proprietary drugs to enhance its immunology portfolio. - **Tharimmune, Inc.**: A company developing therapies for immune diseases, recently advancing its clinical trials and expanding its product pipeline. - **Enanta Pharmaceuticals**: A company advancing its immunology portfolio, particularly targeting Type 2 immune diseases. - **Genentech**: A biotechnology company that has merged its cancer immunology research with molecular oncology to enhance research efficiency. - **Virax Biolabs**: A biotechnology company specializing in immune response detection and viral disease diagnosis, showcasing its products at the European Congress of Immunology. - **Kyowa Kirin**: A global specialty pharmaceutical company collaborating with the La Jolla Institute for Immunology to advance drug discovery in immunology. ### Partnerships and Collaborations - **NImmune Biopharma and BioTherapeutics**: Collaboration to enhance the development of immunoregulatory drugs through advanced preclinical services. - **UCLA and Goodman-Luskin Microbiome Center**: Collaboration within the California Institute for Immunology and Immunotherapy focusing on microbiome research. - **La Jolla Institute for Immunology and Kyowa Kirin**: Renewed partnership to advance drug discovery and development in immunology. - **Ragon Institute and Jameel Clinic at MIT**: Developed MUNIS, a deep learning tool for predicting CD8+ T cell epitopes, enhancing vaccine development. - **University of Texas MD Anderson Cancer Center**: Established the Institute for Cell Therapy Discovery and Innovation to advance research in immunology and cell engineering. - **Moffitt Cancer Center, Dartmouth College, and Duke University**: Collaborative research on gamma-delta T cells to understand their role in cancer treatment. - **Johnson & Johnson and Numab Therapeutics**: Acquisition of a bispecific antibody targeting pathways in atopic dermatitis, enhancing J&J's immunology portfolio. - **Biogen and HI-Bio**: Biogen's acquisition of HI-Bio aims to diversify its portfolio in immunology, focusing on autoimmune disease treatments. - **University of Melbourne and Pfizer**: Joint research on dual-target drug therapies to enhance immune responses against breast cancer. - **Sanofi and Belharra Therapeutics**: Collaboration to explore small molecule drug discovery in immunology, with significant financial backing. - **Halozyme and argenx**: Collaboration for exclusive rights to drug delivery technology enhancing immunology treatments. - **OMNY Health and Scipher Medicine**: Partnered to integrate transcriptomic data with EHR networks to enhance precision medicine for immunology, particularly for rheumatoid arthritis. - **Gilead Sciences and Xilio Therapeutics**: Entered an exclusive licensing agreement to develop a tumor-activated IL-12 program. - **Evaxion Biotech and MSD**: A collaboration to advance the development of preclinical vaccine candidates, enhancing Evaxion's AI-Immunology platform. - **AbbVie and Neomorph**: Collaboration to develop molecular glue degraders targeting proteins involved in cancer and immune system dysregulation. - **Pfizer and CytoReason**: Long-term collaboration leveraging CytoReason's immunology platform to enhance drug development pathways. - **Flagship Pioneering and GSK**: A partnership to invest in research for respiratory and immunology, aiming to identify new medicines and vaccines. - **Evaxion Biotech and Expres2ion Biotechnologies**: Collaboration to develop a cytomegalovirus vaccine candidate, leveraging AI for antigen identification. - **AbbVie and Tentarix Biotherapeutics**: Strategic partnership to develop biologic candidates for oncology and immunology. - **Odyssey Therapeutics and Terray Therapeutics**: Strategic collaboration to discover and develop small molecule medicines for autoimmune diseases. ### Innovations, Trends, and Initiatives - **Immunology Market Growth**: The global immunology market is projected to grow from $110.1 billion in 2023 to $204.0 billion by 2033, driven by chronic disease prevalence and R&D investments. - **California Institute for Immunology and Immunotherapy**: A new institute aimed at advancing immunology research, particularly in vaccine development and microbiome studies. - **AI and Machine Learning in Immunology**: Integration of AI tools like MUNIS to enhance vaccine development and immunotherapy research. - **AI in Immunology**: The integration of artificial intelligence in immunology research and drug development, enhancing patient care and treatment outcomes. - **Synthetic Immunology**: An emerging field aiming to revolutionize treatments for infectious diseases and cancer through innovative approaches, including nanotechnology. - **Precision Immunology**: Emerging trend in developing targeted therapies that minimize effects on healthy tissues, as demonstrated by Santa Ana Bio's funding and research. - **Personalized Medicine**: Growing emphasis on personalized treatment strategies in immunology, particularly in allergy and cancer treatments. - **Cell and Gene Therapies**: Shifting focus from cancer treatment to addressing autoimmune diseases, highlighting the need for innovative immunomodulatory techniques. - **Immunology Scholarship**: AbbVie's initiative to support students with chronic inflammatory diseases, promoting academic success and community leadership. - **AI-Immunology Platform**: Evaxion's platform that identifies antigens for vaccine development, showcasing the integration of AI in immunology. - **Humanized Mouse Models**: Developed by researchers at The University of Texas to improve immunotherapy research and disease modeling. - **Immunotherapy Market Growth**: Projected growth from $240 billion in 2023 to $1.3 trillion by 2033, driven by rising chronic illness prevalence. - **OMNY Health's EHR Network**: Serves over 80 million patients, facilitating data-driven decisions for clinicians and researchers in immunology. - **HFB200604 by HiFiBiO**: A monoclonal antibody designed to restore immune tolerance, currently in clinical trials for inflammatory diseases. - **Dual-Target Antibody Therapy**: Innovative approach to enhance T cell responses against cancer, potentially revolutionizing immunotherapy. ### Challenges and Concerns - **Translational Challenges**: Difficulties in translating laboratory innovations in immunology to clinical applications, requiring interdisciplinary collaboration. - **Unmet Clinical Needs**: Despite advancements, there remain significant unmet clinical needs in immunology, particularly in autoimmune diseases. - **Quality Issues**: Concerns regarding the quality of research antibodies and reagents, which are critical for immunology research. - **Drug Development for Autoimmune Diseases**: Challenges in developing biologic therapies due to potential immune responses, prompting research into safer methods. - **Regulatory Requirements**: Stringent regulations pose challenges for the growth and development of new immunological therapies. - **Underrepresentation in Clinical Research**: Efforts needed to ensure inclusivity and diversity in clinical trials for immune-mediated diseases. - **Access to Treatments**: The need for equitable access to healthcare and treatment options, particularly in immunology and oncology. - **Complexity of Autoimmune Diseases**: Challenges in developing effective treatments due to the complexity of diseases and immune system risks. - **Clinical Development Risks**: The uncertainties and risks associated with clinical trials and the commercialization of new immunology therapies. - **Market Saturation**: The immunology market faces challenges from the saturation of biosimilars, impacting the competitive landscape. - **Healthcare Spending**: Rising healthcare costs and the need for effective management of chronic diseases, including immunological conditions. - **Biosimilars Competition**: The entry of biosimilars poses challenges to traditional immunology product markets, impacting pricing and market share. - **Drug Pricing and Access**: Concerns in the pharmaceutical sector regarding competition from generics and biosimilars affecting immunotherapy pricing. - **High Development Costs**: The immunotherapy market faces challenges due to the high costs associated with drug development and stringent regulatory processes. - **Clinical Trial Failures**: Genentech's challenges with its anti-TIGIT program highlight the difficulties faced in cancer immunotherapy research. - **Patent Expirations**: The pharmaceutical industry faces a $300 billion growth gap due to patent expirations, impacting investment in immunology. - **Legislative Changes**: Proposed dismantling of NIAID could create bureaucratic hurdles and inefficiencies in immunology and infectious disease research. - **Regulatory Hurdles**: Companies like Tharimmune must navigate regulatory feedback and clinical trial challenges as they advance their therapies. - **Biosimilars Impact**: AbbVie faces challenges from biosimilars affecting its flagship product, Humira, although it is expected to maintain strong revenue growth.